Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioconBOM:532523 -0.84%89 Forward Dividend Yield % is 0.11% as of Jul. 19, 2026. GuruFocus rates BOM:532523 with a GF Score™ of 89/100 and a GF Value™ of ₹339.41 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 149 Biotechnology companies, Biocon ranks worse than 97.32% on this metric.
As of today (2026-07-19), the Forward Annual Dividend Yield of Biocon is 0.11%.
As of today (2026-07-19), the Trailing Annual Dividend Yield of Biocon is 0.11%.
BOM:532523's Forward Dividend Yield % is ranked worse than 97.32% of 149
companies
in the Biotechnology industry
Industry Median: 1.32
vs BOM:532523: 0.11
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Biocon was 44.40% per year. The lowest was -33.10% per year. And the median was 18.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BOM:532523 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Biocon's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocon Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biocon's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Biocon's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Biocon Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
INR 0.500000
2026-07-03
2026-07-03
2026-08-20
Cash Dividend
annually
INR:INR 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Biocon's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.5
/
437.00
=
0.11 %
Current Share Price is ₹437.00. Biocon's Dividends per Share for the forward twelve months is calculated as ₹0.5 * 1 = ₹0.5.
Biocon's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.5
/
437.00
=
0.11 %
Current Share Price is ₹437.00. Biocon's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₹0.5.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 0.11% mean?
Biocon (BOM:532523) has a Forward Dividend Yield % of 0.11% as of Jul. 19, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biocon and its competitors. According to the industry distribution chart, Biocon ranks #145 out of 149 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Biocon's Forward Dividend Yield % too high?
Biocon's current Forward Dividend Yield % is 0.11%. The Biotechnology industry median Forward Dividend Yield % is 1.32. Biocon's value of 0.11% is 91.7% below this industry median. Based on the distribution chart, Biocon ranks #145 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocon has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocon ranks #145 out of 149 companies for Forward Dividend Yield %. This places Biocon in the lower half of its industry. The industry median Forward Dividend Yield % is 1.32. Biocon's value of 0.11% is 91.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.32, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocon's current Forward Dividend Yield % of 0.11% is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biocon and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocon's current Forward Dividend Yield % is 0.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (BOM:532523) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.41, compared to a current price of ₹437.00 — trading 28.8% above its estimated fair value. The current Forward Dividend Yield % is 0.11% and 91.7% below the Biotechnology industry median of 1.32. Biocon's overall GF Score™ is 89/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Biocon (BOM:532523), the current Forward Dividend Yield % is 0.11% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (BOM:532523) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹437.00 is trading 28.8% above its estimated GF Value™ of ₹339.41.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for BOM:532523:
Forward Dividend Yield %: 0.11%
GF Value™: ₹339.41 vs. price of ₹437.00 (28.8% above fair value)
Industry Position: 91.7% below the Biotechnology median (#145 of 149)
No single metric tells the full story. See the BOM:532523 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
89GF Score
Get the complete analysis for BOM:532523
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532523 has been successfully added to your 
